New Jersey Assembly Bill A1878

New Jersey 2022-2023 Regular Session

• Introduced: 1/11/22
• Refer: 1/11/22

Caption

Requires pharmacies to provide certain information regarding insulin manufacturer assistance programs.

Impact

The implementation of A1878 is expected to significantly affect state laws concerning pharmacy practices and patient rights. By requiring pharmacies to actively inform customers about available assistance programs, the bill emphasizes the role of pharmacies as essential healthcare providers and information hubs. This change aims to alleviate some of the financial burden faced by individuals who rely on insulin for diabetes management, potentially improving health outcomes and accessibility for patients.

Summary

Assembly Bill A1878 aims to enhance patient access to insulin by requiring pharmacies to provide specific information related to insulin manufacturer assistance programs. The bill mandates that pharmacy practice sites display notices concerning these programs at all points of sale and distribute pamphlets to individuals purchasing insulin prescriptions or requesting this information. The intent is to ensure that patients are aware of any assistance available to help manage their insulin costs, addressing a pressing healthcare issue in New Jersey.

Contention

While A1878 is designed to help patients, it may face opposition from some stakeholders concerned about additional burdens imposed on pharmacies. There are discussions around the practical implications of displaying information and distributing pamphlets, with some arguing that it could overwhelm pharmacy operations and staff. However, proponents of the bill argue that the social benefits of informing patients—and potentially lowering their out-of-pocket costs for insulin—outweigh these operational concerns. Additionally, there may be debates regarding the adequacy and accuracy of the information provided through these programs, as well as the responsibilities of insulin manufacturers in assisting pharmacies.